Assessing the construct validity and responsiveness of Preference-Based Measures (PBMs) in cataract surgery patients.
Bolt-on
Cataract
EQ-5D
ICECAP-O
Responsiveness
Validity
Journal
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
ISSN: 1573-2649
Titre abrégé: Qual Life Res
Pays: Netherlands
ID NLM: 9210257
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
accepted:
08
02
2020
pubmed:
23
2
2020
medline:
28
7
2020
entrez:
22
2
2020
Statut:
ppublish
Résumé
The validity and responsiveness of the EQ-5D-3L in visual conditions has been questioned, inspiring development of a vision 'bolt-on' domain (EQ-5D-3L + VIS). Developments in preference-based measures (PBM) also includes the EQ-5D-5L and the ICECAP-O capability wellbeing measure. This study aimed to examine the construct validity and responsiveness of the EQ-5D-3L, EQ-5D-5L, EQ-5D-3L + VIS and ICECAP-O in cataract surgery patients for the first time, to inform choice of PBM for economic evaluation in this population. The analyses used data from the UK Predict-CAT cataract surgery cohort study. PBMs and the Cat-PROM5 [a validated measure of cataract quality of life (QOL)] were completed before surgery and 4-8 weeks after. Construct validity was assessed using correlations and known-group differences evaluated using regression. Responsiveness was evaluated using effect sizes and analysis of variance to compare change scores between groups, defined by patient-reported and clinical outcomes. The sample comprised 1315 patients at baseline. No PBMs were associated with visual acuity and only the ICECAP-O (Spearman's rs = - 0.35), EQ-5D-3L + VIS (rs = - 0.42) and EQ-5D-5L (Value Set for England rs = - 0.31) correlated at least moderately with the Cat-PROM5. Effect sizes of change were consistently largest for the EQ-5D-3L + VIS (range 0.34-0.41), followed by the ICECAP-O (range 0.20-0.34). Results indicated no improvement in responsiveness using the EQ-5D-5L (range 0.13-0.16) compared to the EQ-5D-3L (range 0.17-0.20). Whilst no PBMs comprehensively demonstrated evidence of construct validity and responsiveness in cataract surgery patients, the ICECAP-O was the most responsive generic PBM to improvements in QOL. Surprisingly the EQ-5D-5L was not more responsive than the EQ-5D-3L in this setting.
Identifiants
pubmed: 32080789
doi: 10.1007/s11136-020-02443-3
pii: 10.1007/s11136-020-02443-3
pmc: PMC7295830
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1935-1946Subventions
Organisme : Department of Health
ID : RP-PG-0611-20013
Pays : United Kingdom
Organisme : Programme Grants for Applied Research
ID : RP-PG-0611-20013
Références
Qual Life Res. 2012 Feb;21(1):167-76
pubmed: 21598064
J Cataract Refract Surg. 2016 Dec;42(12):1759-1767
pubmed: 28007107
Value Health. 2012 May;15(3):550-61
pubmed: 22583466
Health Econ. 2008 Jun;17(6):667-70
pubmed: 18457341
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Value Health. 2012 Jul-Aug;15(5):708-15
pubmed: 22867780
Pharmacoeconomics. 2018 Jun;36(6):699-713
pubmed: 29476363
Optom Vis Sci. 2013 Aug;90(8):861-6
pubmed: 23851304
Pharmacoeconomics. 2018 Jun;36(6):645-661
pubmed: 29572719
Qual Life Res. 2019 Jun;28(6):1429-1439
pubmed: 30666550
Pharmacoeconomics. 2017 Dec;35(Suppl 1):21-31
pubmed: 29052157
Patient. 2019 Aug;12(4):383-392
pubmed: 30607809
Invest Ophthalmol Vis Sci. 2008 Jan;49(1):1-6
pubmed: 18172067
Health Technol Assess. 2014 Feb;18(9):1-224
pubmed: 24524660
Health Econ. 2018 Jan;27(1):7-22
pubmed: 28833869
J Cataract Refract Surg. 2014 Jul;40(7):1163-9
pubmed: 24957436
Value Health. 2015 Jan;18(1):52-60
pubmed: 25595234
JAMA. 2019 Jun 4;321(21):2067-2068
pubmed: 30946431
J Clin Epidemiol. 2011 May;64(5):497-506
pubmed: 20685077
Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3278-81
pubmed: 12882770
J Cataract Refract Surg. 2009 Mar;35(3):504-13
pubmed: 19251145
Health Policy. 1996 Jul;37(1):53-72
pubmed: 10158943
Invest Ophthalmol Vis Sci. 2016 Nov 1;57(14):5872-5881
pubmed: 27802517
Eye (Lond). 2018 Apr;32(4):796-805
pubmed: 29521952
Pharmacoeconomics. 2015 Nov;33(11):1137-54
pubmed: 26040242
J Cataract Refract Surg. 2002 Oct;28(10):1742-9
pubmed: 12388022
Value Health. 2019 Jan;22(1):50-61
pubmed: 30661634
Acta Med Port. 2014 Mar-Apr;27(2):236-45
pubmed: 24813493
Soc Sci Med. 2006 Apr;62(8):1891-901
pubmed: 16168542
Eye (Lond). 2018 Apr;32(4):788-795
pubmed: 29386619
Med Care. 2004 Sep;42(9):851-9
pubmed: 15319610
Soc Sci Med. 2008 Sep;67(5):874-82
pubmed: 18572295
Ophthalmic Epidemiol. 2010 Jun;17(3):152-9
pubmed: 20455844
Appl Health Econ Health Policy. 2017 Apr;15(2):127-137
pubmed: 28194657
Value Health. 2010 Jun-Jul;13(4):487-94
pubmed: 20230549
Health Qual Life Outcomes. 2003 Oct 16;1:54
pubmed: 14613568
BMC Health Serv Res. 2008 Apr 08;8:76
pubmed: 18397519
Br J Ophthalmol. 2007 Jul;91(7):927-32
pubmed: 17272387
Lancet Glob Health. 2017 Dec;5(12):e1221-e1234
pubmed: 29032195